Huang et al13 specifically demonstrated that the magnitude of treatment-induced reinvigoration of circulating exhausted T cells, measured relative to pretreatment tumour burden, correlated with the clinical response to anti-PD1 therapy. This evidence concerns the gene PDCD1 and neoplasm.